Amneal Pharmaceuticals, Inc. Class A Common Stock
Here’s whether Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bullish.
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+3.25% over 10 days); strong 1-year return of +103.5%; 3-month momentum positive (+35.7%); rising volume confirms the move (1.18x 30d avg). Concerns: RSI 86 — overbought, elevated pullback risk. Currently 2.5% off its 52-week high. Score: +6/7.
AMRX is in a confirmed uptrend, trading above both its 50-day ($13.05) and 200-day ($12.25) moving averages. With an RSI of 86.3, momentum has stretched into overbought territory — short-term pullbacks are common from these levels. The 1-year return of +103.5% compares to +22.9% for SPY (beat the market by 80.7%).